The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve’s biggest gene therapies has already received the FDA’s fast track designation.
The company’s SSi Mantra 3 robotic surgery system has already gained regulatory approvals in several countries. FDA approval is anticipated by late 2025 or early 2026.
The company’s SSi Mantra 3 robotic surgery system has already gained regulatory approvals in several countries. FDA approval is anticipated by late 2025 or early 2026.
Janet Wei, MD, examined the key differences between men and women when it comes to cardiovascular disease. These differences, she said, highlight why female patients…
The three-day event is now in its second year. Each day will feature late-breaking clinical trials focused on a different heart valve.
The San Diego-based startup gained FDA approval for its Hotwire RF guidewire in 2024. The technology has already been used to perform hundreds of heart…
American College of Cardiology Board of Trustees Chair David E. Winchester, MD, MS, examines the many benefits of working with with the American Medical Association…
“Just as medicine has its own language, so does business,” two surgeons explained in a new editorial.
The EARLY TAVR clinical trial made a significant impact, paving the way for the FDA to approve multiple transcatheter heart valves for the treatment of…
The Aventus Thrombectomy System was already cleared to treat blood clots in the peripheral arteries. This latest approval comes after positive results from an IDE…
Even TAVR patients not treated using transfemoral access can typically go home the very next day.
